❌

Normal view

From User Interface to Agent Interface: Efficiency Optimization of UI Representations for LLM Agents

arXiv:2512.13438v1 Announce Type: cross Abstract: While Large Language Model (LLM) agents show great potential for automated UI navigation such as automated UI testing and AI assistants, their efficiency has been largely overlooked. Our motivating study reveals that inefficient UI representation creates a critical performance bottleneck. However, UI representation optimization, formulated as the task of automatically generating programs that transform UI representations, faces two unique challenges. First, the lack of Boolean oracles, which traditional program synthesis uses to decisively validate semantic correctness, poses a fundamental challenge to co-optimization of token efficiency and completeness. Second, the need to process large, complex UI trees as input while generating long, compositional transformation programs, making the search space vast and error-prone. Toward addressing the preceding limitations, we present UIFormer, the first automated optimization framework that synthesizes UI transformation programs by conducting constraint-based optimization with structured decomposition of the complex synthesis task. First, UIFormer restricts the program space using a domain-specific language (DSL) that captures UI-specific operations. Second, UIFormer conducts LLM-based iterative refinement with correctness and efficiency rewards, providing guidance for achieving the efficiency-completeness co-optimization. UIFormer operates as a lightweight plugin that applies transformation programs for seamless integration with existing LLM agents, requiring minimal modifications to their core logic. Evaluations across three UI navigation benchmarks spanning Android and Web platforms with five LLMs demonstrate that UIFormer achieves 48.7% to 55.8% token reduction with minimal runtime overhead while maintaining or improving agent performance. Real-world industry deployment at WeChat further validates the practical impact of UIFormer.

VeriMoA: A Mixture-of-Agents Framework for Spec-to-HDL Generation

arXiv:2510.27617v1 Announce Type: new Abstract: Automation of Register Transfer Level (RTL) design can help developers meet increasing computational demands. Large Language Models (LLMs) show promise for Hardware Description Language (HDL) generation, but face challenges due to limited parametric knowledge and domain-specific constraints. While prompt engineering and fine-tuning have limitations in knowledge coverage and training costs, multi-agent architectures offer a training-free paradigm to enhance reasoning through collaborative generation. However, current multi-agent approaches suffer from two critical deficiencies: susceptibility to noise propagation and constrained reasoning space exploration. We propose VeriMoA, a training-free mixture-of-agents (MoA) framework with two synergistic innovations. First, a quality-guided caching mechanism to maintain all intermediate HDL outputs and enables quality-based ranking and selection across the entire generation process, encouraging knowledge accumulation over layers of reasoning. Second, a multi-path generation strategy that leverages C++ and Python as intermediate representations, decomposing specification-to-HDL translation into two-stage processes that exploit LLM fluency in high-resource languages while promoting solution diversity. Comprehensive experiments on VerilogEval 2.0 and RTLLM 2.0 benchmarks demonstrate that VeriMoA achieves 15--30% improvements in Pass@1 across diverse LLM backbones, especially enabling smaller models to match larger models and fine-tuned alternatives without requiring costly training.

Identification of C4BPA as a genetically informed drug target in NSCLC: an integrative single-cell and multi-omics study based on the druggable genes

Hum Genomics. 2025 Oct 6;19(1):113. doi: 10.1186/s40246-025-00829-3.

ABSTRACT

BACKGROUND: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide. Despite advancements in treatment, drug resistance and limited therapeutic efficacy persist, underscoring the urgent need for novel and mechanistically informed therapeutic strategies. Identifying genetically supported drug targets may accelerate the development of precision therapies in NSCLC.

METHODS: We implemented an integrative multi-omics framework combining single-cell RNA sequencing (scRNA-seq), genome-wide association studies (GWAS), and molecular quantitative trait locus (QTL) datasets including expression (eQTL), protein (pQTL), and DNA methylation (mQTL) QTLs. Druggable candidates were systematically evaluated using a suite of Mendelian randomization (MR) approaches-including summary data-based MR (SMR), generalized SMR (GSMR), and genetic risk score (GRS) analysis. Epigenetic regulation and downstream signaling were further explored through mediation MR analysis.

RESULTS: C4BPA, a complement-regulatory macromolecule, emerged as a risk factor for NSCLC across multiple MR models, with consistent findings validated at both transcriptomic and proteomic levels. Epigenetic activation of C4BPA via DNA methylation was observed, and C4BPA expression was shown to promote NSCLC progression through the inflammatory chemokine CCL8 signaling axis. Sensitivity analyses confirmed the robustness of association inference.

CONCLUSIONS: Our findings identify C4BPA as a genetically validated and biologically plausible therapeutic target for NSCLC. This study demonstrates the power of integrating single-cell transcriptomics with population-scale omics and association inference to uncover actionable targets, offering a scalable framework for advancing precision oncology in lung cancer.

PMID:41053817 | PMC:PMC12502296 | DOI:10.1186/s40246-025-00829-3

A 23-gene multi-omics signature predicts prognosis and treatment response in non-small cell lung cancer

Discov Oncol. 2025 Jul 23;16(1):1391. doi: 10.1007/s12672-025-03243-2.

ABSTRACT

We developed the first multi-omics prognostic signature integrating 19 programmed cell death (PCD) pathways and organelle functions (mitochondria, lysosomes, Golgi apparatus) to predict prognosis and immunotherapy response in non-small cell lung cancer (NSCLC). (2) Methods: By combining single-cell RNA-seq, bulk transcriptomics, and deep neural networks (DNN), we identified a 23-gene signature validated across four cohorts (AUC 0.696–0.812). Conducted MR analysis to explore causal links between signature genes and NSCLC incidence, providing biological insights. (3) Results: A prognostic signature was developed, including 23 prognostic genes related to 19 PCD patterns and three organelle functions. The signature demonstrated powerful performance in predicting NSCLC prognosis, immune in-filtration, and therapeutic response. Established DNN models showed high value in predicting risk score groupings of NSCLC. MR analysis for combined SNP information of the 23 prognostic genes suggested a link to the high incidence of NSCLC. Individual MR analysis showed that HIF1A and SQLE expression had a causal effect on NSCLC incidence. (4) Conclusion: This signature stratifies high-risk patients with immunosuppressive microenvironments and predicts enhanced sensitivity to gemcitabine and PD-1 inhibitors, offering a roadmap for personalized NSCLC management.

SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12672-025-03243-2.

PMID:40699399 | PMC:PMC12287486 | DOI:10.1007/s12672-025-03243-2

  • ✇MRD
  • Liquid biopsies in cancer Hang Yin · Manjie Zhang · Yu Zhang · Xuebing Zhang · Xia Zhang · Bin Zhang
    Mol Biomed. 2025 Mar 20;6(1):18. doi: 10.1186/s43556-025-00257-8.ABSTRACTCancer ranks among the most lethal diseases worldwide. Tissue biopsy is currently the primary method for the diagnosis and biological analysis of various solid tumors. However, this method has some disadvantages related to insufficient tissue specimen collection and intratumoral heterogeneity. Liquid biopsy is a noninvasive approach for identifying cancer-related biomarkers in peripheral blood, which allows for repetitive s
     

Liquid biopsies in cancer

20 March 2025 at 18:00

Mol Biomed. 2025 Mar 20;6(1):18. doi: 10.1186/s43556-025-00257-8.

ABSTRACT

Cancer ranks among the most lethal diseases worldwide. Tissue biopsy is currently the primary method for the diagnosis and biological analysis of various solid tumors. However, this method has some disadvantages related to insufficient tissue specimen collection and intratumoral heterogeneity. Liquid biopsy is a noninvasive approach for identifying cancer-related biomarkers in peripheral blood, which allows for repetitive sampling across multiple time points. In the field of liquid biopsy, representative biomarkers include circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes. Many studies have evaluated the prognostic and predictive roles of CTCs and ctDNA in various solid tumors. Although these studies have limitations, the results of most studies appear to consistently demonstrate the correlations of high CTC counts and ctDNA mutations with lower survival rates in cancer patients. Similarly, a reduction in CTC counts throughout therapy may be a potential prognostic indicator related to treatment response in advanced cancer patients. Moreover, the biochemical characteristics of CTCs and ctDNA can provide information about tumor biology as well as resistance mechanisms against targeted therapy. This review discusses the current clinical applications of liquid biopsy in cancer patients, emphasizing its possible utility in outcome prediction and treatment decision-making.

PMID:40108089 | PMC:PMC11923355 | DOI:10.1186/s43556-025-00257-8

Efficient discovery of robust prognostic biomarkers and signatures in solid tumors

Cancer Lett. 2025 Mar 31;613:217502. doi: 10.1016/j.canlet.2025.217502. Epub 2025 Jan 24.

ABSTRACT

Recent advancements in multi-omics and big-data technologies have facilitated the discovery of numerous cancer prognostic biomarkers and gene signatures. However, their clinical application remains limited due to poor reproducibility and insufficient independent validation. Despite the availability of high-quality datasets, achieving reliable biomarker identification across multiple cohorts continues to be a significant challenge. To address these issues, we developed a comprehensive platform, SurvivalML, designed to support the discovery and validation of prognostic biomarkers and gene signatures using large-scale and harmonized data from 21 cancer types. Through SurvivalML, we identified DCLRE1B as a novel prognostic biomarker for hepatocellular carcinoma, with experimental confirmation of its role in promoting tumor progression. Additionally, we developed the Chinese glioblastoma prognostic signature (CGPS) and its simplified version, SCGPS, a three-gene model. Both demonstrated superior predictive performance compared to other glioblastoma signatures in our in-house cohort and five independent Chinese datasets. The SCGPS model was further validated in 109 clinical samples using multiplex immunofluorescence, showing strong consistency with the original CGPS model. Overall, SurvivalML provides a robust platform for the identification and validation of prognostic biomarkers and gene signatures, offering a valuable resource for advancing cancer research and clinical application.

PMID:39864538 | DOI:10.1016/j.canlet.2025.217502

ScRNA-seq of gastric cancer tissues reveals differences in the immune microenvironment of primary tumors and metastases

Oncogene, Published online: 30 March 2024; doi:10.1038/s41388-024-03012-5

ScRNA-seq of gastric cancer tissues reveals differences in the immune microenvironment of primary tumors and metastases
❌